Publicacions en col·laboració amb investigadors/es de Claude Bernard University Lyon 1 (7)

2024

  1. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

    Blood, Vol. 143, Núm. 17, pp. 1713-1725

2022

  1. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

    New England Journal of Medicine, Vol. 386, Núm. 7, pp. 629-639

  2. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

    Nature Medicine, Vol. 28, Núm. 2, pp. 325-332

2021

  1. Common gene variants within 3′-untranslated regions as modulators of multiple myeloma risk and survival

    International Journal of Cancer, Vol. 148, Núm. 8, pp. 1887-1894

  2. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 18, pp. 1959-1970

2015

  1. Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients

    Nature Communications, Vol. 6

2014

  1. Genetic variants and multiple myeloma risk: IMMEnSE validation of the best reported associations - An extensive replication of the associations from the candidate gene era

    Cancer Epidemiology Biomarkers and Prevention, Vol. 23, Núm. 4, pp. 670-674